Mesoblast Reports Ryoncil Net Revenues for Q4 and Full Year
Key points
- Ryoncil net revenue for Q4: US$36M
- Full year net revenue: US$115M
- Expansion of Ryoncil indications in progress
- Pivotal Phase 3 trial for CLBP completed target enrollment
- New CAR technology platform acquisition announced
Full summary
Mesoblast Limited, a leader in allogeneic cellular medicines for inflammatory diseases, reported net revenues of US$36M for Ryoncil in Q4 and US$115M for the full year. The company is expanding Ryoncil's FDA-approved label to include adults with steroid-refractory acute graft versus host disease (SR-aGvHD) and other severe inflammatory conditions. A registration trial for Ryoncil in adults with SR-aGvHD is underway. Mesoblast also received FDA clearance for a trial of Ryoncil in children with Duchenne muscular dystrophy. Additionally, Mesoblast achieved its target enrollment of 300 patients in the pivotal Phase 3 trial for rexlemestrocel-L for chronic low back pain. The company held an R&D day, unveiling next-generation mesenchymal stromal cell strategies, including acquiring a license for a CAR technology platform.
Summary generated by a large language model. Please interpret with care.